AbClon Inc.
KOE: 174900.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Industrials
- Industry
- Specialty Business Services
- CEO
- Kim Kyu-Tae
- Employees
- 66
- Headquarters
- Seoul, South Korea
- IPO year
- 2017
- Market cap
- ₩853.5B
- Website
- https://www.abclon.com
Loading 174900…
Loading profile data…Frequently asked questions about 174900
What does AbClon Inc. (174900.KQ) do?
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ova...
Where does 174900.KQ trade?
AbClon Inc. (174900.KQ) trades on the KOSDAQ.
What sector is 174900.KQ in?
AbClon Inc. (174900.KQ) operates in the Industrials sector, specifically in the Specialty Business Services industry.
Who is the CEO of AbClon Inc.?
Kim Kyu-Tae is the chief executive officer of AbClon Inc. (174900.KQ).
Where is AbClon Inc. headquartered?
AbClon Inc. is headquartered in South Korea.
Does 174900.KQ pay a dividend?
AbClon Inc. (174900.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 174900.KQ go public?
AbClon Inc. (174900.KQ) completed its initial public offering in 2017.